Ardena cements growth and expansion with new HQ

12 Nov 2018

Larger headquarters will enable the company to free up space for additional laboratories and further expand capabilities.

CDMO Ardena has cemented a sustained period of growth with a move to expanded headquarters in Gent, Belgium.

Ardena cements growth and expansion with new HQ

Since 2015, Ardena has grown from 40 to 250 staff members and seen more than 20% organic growth per year, fueled by the CDMO’s M&A strategy which has seen four acquisitions in the past 2 years, most recently Netherlands-based ChemConnection and Sweden-based Syntagon.

It now operates across six sites in Belgium, the Netherlands, Sweden and Latvia and boasts a global reach, servicing more than 300 customers in Europe, the US, Japan and Korea.

Ardena offers integrated drug development services encompassing drug substance and drug product development, clinical manufacturing, clinical logistics, full product analytical and bioanalytical support and regulatory dossier development. The company is also a leader in nanomedicine technology.

Harry Christiaens, CEO at Ardena said: “After several acquisitions and an ongoing growth period, we are firmly on track to reach our €35 million sales target for 2018 as part of our wider strategy to become a leading integrated drug development company.

“This new, larger headquarters will enable us to free up space for additional laboratories at our other sites and further expand our capabilities. It will also provide a base for our staff training centre to ensure we develop our team.

“As we move into 2019, we look forward to continued international success and carrying on with our acquisition strategy to further strengthen our service offering.”

Ardena was formed in 2017, following the merging of three companies with complementary drug development capabilities: Pharmavize in Belgium, and Crystallics and Analytical Biochemical Laboratory (ABL) in the Netherlands.

Read More

Related news

Specialist API CDMO acquired by GHO Capital

Specialist API CDMO acquired by GHO Capital

16 Mar 2019

Future plan is to extend Sterling’s international presence to meet increasing demand from customers worldwide.

Read more 
Bringing next generation single-use sensor technologies to the life science market

Bringing next generation single-use sensor technologies to the life science market

14 Mar 2019

Pall and Broadley-James’ combined expertise proves complementary in addressing critical customer pain points in modern bioprocessing.

Read more 
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

13 Mar 2019

Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.

Read more 
TraceLink submits an interoperable blockchain network solution for FDA DSCSA Pilot Project Program

TraceLink submits an interoperable blockchain network solution for FDA DSCSA Pilot Project Program

12 Mar 2019

Trace Histories is a purpose-built distributed ledger solution for ensuring patient safety by 2023 DSCSA deadline.

Read more 
Overcoming lyophilization challenges at Interphex 2019

Overcoming lyophilization challenges at Interphex 2019

10 Mar 2019

Line of Sight approach to freeze-drying enables organizations to bring pharmaceutical products safely and quickly to market.

Read more 
Catalent invests over $27 million to commercialize Zydis Ultra

Catalent invests over $27 million to commercialize Zydis Ultra

7 Mar 2019

Zydis Ultra allows a patented and innovative drug coating to be introduced during a product’s formulation, enabling the dosage of active ingredient to be up to four times higher than a conventional Zydis ODT.

Read more 
Novel systems for membrane chromatography

Novel systems for membrane chromatography

6 Mar 2019

Optimally run membrane chromatography processes will provide higher productivity, smaller-scale operations and increased robustness.

Read more 
Lilly to introduce lower-priced insulin

Lilly to introduce lower-priced insulin

5 Mar 2019

Authorized generic version of Humalog will be available in US pharmacies at 50% lower list price.

Read more 
Biogen acquisition boosts its ophthalmology pipeline

Biogen acquisition boosts its ophthalmology pipeline

4 Mar 2019

Nightstar Therapeutics has two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs.

Read more 
Uniqsis expands LED photoreactor range

Uniqsis expands LED photoreactor range

3 Mar 2019

The availability of three new alternative switchable LED configurations provides chemists with the unique ability to optimally undertake almost any photochemistry reaction.

Read more